Wayland Group (CNSX:WAYL) (FRA:75M) (OTCMKTS:MRRCF) CEO Ben Ward sees the company as a trendsetter in the cannabis space. Ward believes that “you have to make the moves ahead of time, you have to plan, and if you’re just following the trends, piling on to the latest and greatest craze of things like funded capacity , registered patients, you’re really behind the ball and then you’re a follower, not a leader.” Wayland’s forward-thinking approach led the company to acquire its EU GMP certification nearly two years ago and is now a leader in Western Europe’s medical cannabis space. Wayland is one of only four companies with EU GMP certification to export cannabis to Europe and it intends to move more Canadian product to countries like Germany while there is no domestic production. Ward anticipates increased stability in the medical cannabis space globally by 2024 and is particularly excited by the potential of the Italian market, where regulators are also interested in the profitability of the industry.

James West:    Welcome back. My guest returning to the show is Ben Ward, CEO of Wayland Group, trading on the CSE under the symbol WAYL. Ben, welcome back.

Ben Ward:Thanks so much for having me, James.

James West:    And every time I talk to you, the developments within Wayland are leapfrogging the last development, and so, you know, I’ve got to say I’m just very impressed. So right now, it was interesting: we were talking earlier, and we were talking about EU GMP-certified facilities who are actually in a po